Showing results (11-20 of 43) with videos related to
Sort By:
Pageof 5
Journal of Medical Systems|May 8, 2020
Pathologist Opinions about EPIC Beaker AP: a Multi-Institutional Survey of Early AdoptersMandy VanSandt, Kevin Turner, Raj Dash, et al.Journal of General Internal Medicine|August 21, 2020
Going Skin Deep: Excavating a Diagnosis of Intravascular Large B Cell LymphomaLaura Oppegard, Matthew O'Donnell, Kevin Piro, et al.Clinical Kidney Journal|July 24, 2020
Anti-LRP2 nephropathy with concurrent kidney infiltration by lymphomaAshley Gamayo, Douglas Hecox, Lance Dicker, et al.Journal of Hematology & Oncology|April 3, 2016
Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agentJessica T Leonard, Philipp W Raess, Jennifer Dunlap, et al.Endocrine Pathology|April 23, 2015
Overlapping Morphologic and Immunohistochemical Features of Hashimoto Thyroiditis and IgG4-Related Thyroid DiseasePhilipp W Raess, Arlette Habashi, Edward El Rassi, et al.American Journal of Clinical Pathology|May 6, 2020
Histology-Independent Signature Distinguishes Kikuchi-Fujimoto Disease/Systemic Lupus Erythematosus-Associated Lymphadenitis From Benign and Malignant LymphadenopathiesGregory D Scott, Jyoti Kumar, Jean S Oak, et al.The Journal of Molecular Diagnostics : JMD|December 24, 2019
Molecular Discordance between Myeloid Sarcomas and Concurrent Bone Marrows Occurs in Actionable Genes and Is Associated with Worse Overall SurvivalBrian Werstein, Jennifer Dunlap, Michael J Cascio, et al.American Journal of Hematology|February 2, 2021
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignanciesSarah J Nagle, Catherine Murphree, Philipp W Raess, et al.Leukemia & Lymphoma|September 5, 2017
MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypesPhilipp W Raess, Stephen R Moore, Michael J Cascio, et al.American Journal of Hematology|May 31, 2019
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLJennifer B Dunlap, Jessica Leonard, Mara Rosenberg, et al.Pageof 5